Navigation Links
Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
Date:6/16/2008

was a phase II study of Schering Plough's CCR5 antagonist, vicriviroc, in highly treatment experienced HIV patients. This new analysis compared treatment outcomes based on the prospective selection of patients with R5 tropic virus by the original Trofile test versus treatment outcomes based on the re-classification using the enhanced version of the assay.

The ACTG 5211 study enrolled subjects who had R5 virus at screening as determined by the original Trofile assay. The analysis reported at this week's workshop demonstrated that recent enhancements to Trofile enable the assay to further optimize patient selection for CCR5 antagonist treatment by successfully identifying patients that experienced reduced virologic response to vicriviroc. In the patients originally identified as R5 tropic, based on test results obtained with the newly enhanced sensitivity of Trofile, greater reductions in viral load were observed in vicriviroc recipients confirmed to have pure R5 virus populations (1.95 log reduction at week 24) compared to those newly re-classified as having minor subpopulations of CXCR4-using virus (0.57 log reduction at week 24) (P<0.001).

Additional work described at the meeting focused on the use of Monogram's phenotypic and genotypic technology to identify specific markers of HIV resistance to new drug targets/classes. Monogram has assays in advanced development that accurately assess resistance to CCR5 antagonists such as maraviroc (Selzentry, Pfizer) and vicriviroc (Schering-Plough), and integrase inhibitors such as raltegravir (Isentress, Merck) and elvitegravir (Gilead Sciences).

Trofile, incorporating sensitivity enhancements, together with PhenoSense(TM), PhenoSenseGT(TM) and GeneSeq(TM) HIV drug resistance assays constitute Monogram's portfolio of assays for the optimization of antiretroviral therapy for HIV infection. Determining a patient's HIV profile at the molecular and phenotypic level, and the effect of therapy on that profile
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
2. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
3. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
6. Study Reaffirms Superiority of Trofile(TM) Assay
7. New York Medicaid Program Establishes Coverage for Trofile(TM)
8. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
9. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Avure Technologies celebrates a year ... newest member of its fleet of high volume High Pressure ... anniversary as we return to PackExpo this year, which is ... Las Vegas,” said Jeff Williams, CEO at Avure. “Sales of ... pleased to be meeting the challenges of market demand for ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 /PRNewswire/ ... GNBT) today announced two presentations demonstrating that the ... novel proprietary cancer immunotherapeutic AE37 vaccine correlated with ... The AE37 cancer vaccine is being developed by ... www.antigenexpress.com ). The presentations are being made at ...
(Date:10/27/2014)... The report “Smart Highway Market by Technology ... and by Display (Variable Message Signs, Digital Signage) ... market into various sub-segments with in-depth analysis and ... and restraints for this market with insights into ... tables and 37 figures spread through 141 pages ...
Breaking Biology Technology:In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4
... , , WILMINGTON, Del., ... dispersible tablet (ODT) technologies with its patented Pharmaburst(R) and Pharmafreeze(TM) ... proprietary technology with superior organoleptics, Pharmaburst(R) 500 will most certainly ... formulators have come to expect from a quick-dissolve dosage form. ...
... WALTHAM, Mass., Aug. 11 Decision Resources, one of ... issues, finds that the entry and uptake of premium-priced biologics will ... from approximately $420 million in 2008 to nearly $2 billion in ... Systemic Lupus Erythematosus finds that the primary drivers of ...
... COLUMBIA, Md., Aug. 11 BP and Martek Biosciences ... a Joint Development Agreement (JDA) to work on the production of ... platform and operational capabilities to advance the development of a step-change ... , Under the terms of the multi-year agreement, Martek ...
Cached Biology Technology:Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4
(Date:10/28/2014)... National University of Singapore (NUS) have discovered a new ... laying direct developing eggs in live bamboo with narrow ... bush frog ( Raorchestes chalazodes ). This critically ... known to adopt this novel reproductive strategy. The findings ... Biological Journal of the Linnean Society , in October ...
(Date:10/28/2014)... University Singapore (NTU Singapore) will be building a ... energy sources. , The first in the region, ... integration of solar, wind, tidal-current, diesel, storage and ... well together. , To be built under the ... the hybrid micro-grid will be located offshore at ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
Breaking Biology News(10 mins):NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... year in the Horn of Africa affected millions of people ... of several migratory songbird species, a study from University of ... the migration route was revealed by data collected from small ... an extended stay in the Horn of Africa. , The ...
... Entomologist Marshall Johnson , an extension specialist and ... the Distinguished Scientist of the Year Award from the ... (IOBC-NRS). Only one individual is recognized annually for ... career in the nearctic region , which encompasses ...
... DNA self-assembly techniques, researchers have developed a new ... the time required to create and test medications. ... Foundation (NSF) Small Business Innovation Research grant, researchers ... and began evaluating a drug for combating the ...
Cached Biology News:Drought in the Horn of Africa delays migrating birds 2UC Riverside entomologist named Distinguished Scientist of the Year 2Drag-and-drop DNA 2Drag-and-drop DNA 3Drag-and-drop DNA 4
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
... For use in hybridization incubators ... and GL 45 size PP plug-seal ... seal. Available in three lengths to ... plug-seal caps and O-rings available separately. ...
... extraction of DNA from agarose gels The SpinPrep ... of 150 bp to > 12,000 bp in size ... dissolve the gel slice, followed by adsorption of the ... format. After a wash step, the purified DNA is ...
Biology Products: